ALMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alumis Inc (ALMS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as insider buying and bullish technical indicators, the lack of recent AI or SwingMax trading signals, absence of significant news, and mixed analyst ratings suggest a cautious approach. Additionally, the stock's short-term trend indicates a potential decline, making it less appealing for immediate investment.
The technical indicators for ALMS are moderately bullish. The MACD is positive and expanding, the RSI is neutral at 66.075, and the moving averages show a bullish alignment (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 24.033 and 25.56, while support levels are at 19.09 and 17.563.
Insiders are buying significantly, with a 586.17% increase in buying activity over the last month. Analysts from Chardan, Morgan Stanley, Guggenheim, and Wells Fargo have raised price targets, reflecting optimism about the company's drug pipeline and financial updates.
H.C. Wainwright downgraded the stock to Neutral, citing valuation concerns. The short-term stock trend suggests a potential decline of -1.62% in the next day, -2.97% in the next week, and -2.49% in the next month. No recent news or congress trading data is available, and there are no AI or SwingMax trading signals.
No financial data is available for the latest quarter, making it difficult to assess the company's growth trends.
Analyst ratings are mixed. While several analysts have raised price targets and maintained Buy or Overweight ratings, one analyst downgraded the stock to Neutral, citing valuation concerns. Price targets range from $25 to $55, with a median target around $39-$40.
